Alder BioPharmaceuticals, Inc. (ALDR) Expected to Post Earnings of -$1.08 Per Share

Wall Street analysts predict that Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) will report earnings per share of ($1.08) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Alder BioPharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($1.54) and the highest estimate coming in at ($0.87). Alder BioPharmaceuticals posted earnings per share of ($0.97) in the same quarter last year, which would suggest a negative year-over-year growth rate of 11.3%. The firm is scheduled to report its next earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that Alder BioPharmaceuticals will report full year earnings of ($5.14) per share for the current financial year, with EPS estimates ranging from ($5.94) to ($4.50). For the next financial year, analysts expect that the company will post earnings of ($3.90) per share, with EPS estimates ranging from ($5.42) to ($2.84). Zacks’ EPS calculations are an average based on a survey of research analysts that follow Alder BioPharmaceuticals.

Alder BioPharmaceuticals (NASDAQ:ALDR) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.21) by $0.29. During the same quarter in the prior year, the business posted ($0.70) earnings per share.

A number of equities analysts have recently commented on ALDR shares. BMO Capital Markets reissued a “buy” rating and issued a $22.00 price target on shares of Alder BioPharmaceuticals in a research report on Wednesday, January 3rd. Mizuho reissued a “buy” rating and issued a $29.00 price target (down previously from $32.00) on shares of Alder BioPharmaceuticals in a research report on Tuesday, January 9th. Canaccord Genuity started coverage on shares of Alder BioPharmaceuticals in a research report on Thursday, October 26th. They issued a “buy” rating and a $20.00 price target on the stock. BidaskClub raised shares of Alder BioPharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, January 4th. Finally, Cowen started coverage on shares of Alder BioPharmaceuticals in a research report on Tuesday, September 26th. They issued an “outperform” rating and a $20.00 price target on the stock. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $27.93.

Alder BioPharmaceuticals (ALDR) opened at $16.80 on Friday. Alder BioPharmaceuticals has a 52-week low of $8.60 and a 52-week high of $25.45. The company has a market cap of $1,139.76, a P/E ratio of -3.13 and a beta of 2.48.

In related news, insider Mark James Litton sold 16,519 shares of the business’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $10.80, for a total transaction of $178,405.20. Following the transaction, the insider now owns 116,451 shares of the company’s stock, valued at $1,257,670.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 10.60% of the company’s stock.

A number of hedge funds have recently made changes to their positions in ALDR. Janus Henderson Group PLC bought a new position in Alder BioPharmaceuticals during the second quarter worth $36,956,000. Pinnacle Associates Ltd. bought a new stake in Alder BioPharmaceuticals in the 3rd quarter valued at $14,823,000. Pictet Asset Management Ltd. increased its holdings in Alder BioPharmaceuticals by 159.4% in the 3rd quarter. Pictet Asset Management Ltd. now owns 1,650,540 shares of the biopharmaceutical company’s stock valued at $20,219,000 after buying an additional 1,014,290 shares during the period. AXA increased its holdings in Alder BioPharmaceuticals by 199.9% in the 3rd quarter. AXA now owns 992,083 shares of the biopharmaceutical company’s stock valued at $12,153,000 after buying an additional 661,253 shares during the period. Finally, Schroder Investment Management Group bought a new stake in Alder BioPharmaceuticals in the 3rd quarter valued at $6,721,000. 96.80% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: “Alder BioPharmaceuticals, Inc. (ALDR) Expected to Post Earnings of -$1.08 Per Share” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/21/alder-biopharmaceuticals-inc-aldr-expected-to-post-earnings-of-1-08-per-share.html.

About Alder BioPharmaceuticals

Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder’s lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention.

Get a free copy of the Zacks research report on Alder BioPharmaceuticals (ALDR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)

Receive News & Ratings for Alder BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alder BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply